{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:06:28Z","timestamp":1781690788863,"version":"3.54.5"},"reference-count":31,"publisher":"Korean Cancer Association","issue":"4","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:p>Purpose The risk stratification of pediatric anaplastic large cell lymphoma (ALCL) has not been standardized. In this study, new risk factors were included to establish a new risk stratification system for ALCL, and its feasibility in clinical practice was explored.Materials and Methods On the basis of the non-Hodgkin\u2019s lymphoma Berlin\u2013Frankfurt\u2013Munster 95 (NHL-BFM-95) protocol, patients with minimal disseminated disease (MDD), high-risk tumor site (multiple bone, skin, liver, and lung involvement), and small cell\/lymphohistiocytic (SC\/LH) pathological subtype were enrolled in risk stratification. Patients were treated with a modified NHL-BFM-95 protocol combined with an anaplastic lymphoma kinase inhibitor or vinblastine (VBL).Results A total of 136 patients were enrolled in this study. The median age was 8.8 years. The 3-year event-free survival (EFS) and overall survival of the entire cohort were 77.7% (95% confidence interval [CI], 69.0% to 83.9%) and 92.3% (95% CI, 86.1% to 95.8%), respectively. The 3-year EFS rates of low-risk group (R1), intermediate-risk group (R2), and high-risk group (R3) patients were 100%, 89.5% (95% CI, 76.5% to 95.5%), and 67.9% (95% CI, 55.4% to 77.6%), respectively. The prognosis of patients with MDD (+), stage IV cancer, SC\/LH lymphoma, and high-risk sites was poor, and the 3-year EFS rates were 45.3% (95% CI, 68.6% to 19.0%), 65.7% (95% CI, 47.6% to 78.9%), 55.7% (95% CI, 26.2% to 77.5%), and 70.7% (95% CI, 48.6% to 84.6%), respectively. At the end of follow-up, one of the five patients who received maintenance therapy with VBL relapsed, and seven patients receiving anaplastic lymphoma kinase inhibitor maintenance therapy did not experience relapse.Conclusion This study has confirmed the poor prognostic of MDD (+), high-risk site and SC\/LH, but patients with SC\/LH lymphoma and MDD (+) at diagnosis still need to receive better treatment (ClinicalTrials.gov number, NCT03971305).<\/jats:p>","DOI":"10.4143\/crt.2024.104","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:13:10Z","timestamp":1716948790000},"page":"1252-1261","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study"],"prefix":"10.4143","volume":"56","author":[{"given":"Tingting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuequn","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mincui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2013.805347"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199605093341906"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.12.3699"},{"key":"ref4","first-page":"3365","volume-title":"Decipher the 2016 revision of the World Health Organization classification of lymphoid neoplasms","author":"Yi","year":"2016"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.5411"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18467"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00157"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.34.8417"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102747"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-526202"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403888"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-066852"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100958"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000109472"},{"key":"ref15","first-page":"332","volume-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","author":"Murphy","year":"1980"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.1487"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21817"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3083"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015142088"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.4830"},{"key":"ref22","first-page":"574","volume-title":"Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed\/refractory CD30 positive lympho-proliferative disorders: a single centre experience","author":"Mediwake","year":"2017"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009806"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00272"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.5999"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1562182"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.205"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2338-6"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071703"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232314"},{"key":"ref31","first-page":"1009","volume-title":"Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study","author":"Brink","year":"2022"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.104","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T23:45:38Z","timestamp":1728863138000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.104","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"2024-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-28","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}